`__________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`
`v.
`
`ADAPT PHARMA OPERATIONS LIMITED, and
`OPIANT PHARMACEUTICALS, INC.,
`Patent Owners.
`__________________
`
`Case IPR2019-00694
`U.S. Patent No. 9,629,965
`__________________
`
`PATENT OWNERS’ MOTION TO SEAL
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 35 U.S.C. § 316(a)(1) and 37 C.F.R. §§ 42.14 and 42.54, Patent
`
`Owners Adapt Pharma Operations Limited (“Adapt”) and Opiant Pharmaceuticals,
`
`Inc. (“Opiant”) hereby move to seal Exhibits 2098–2109, 2188, 2205, and 2207,
`
`which are being filed concurrently with this Motion and Patent Owners’ Response.
`
`I.
`
`DOCUMENTS TO BE SEALED AND REASONS FOR SEALING
`
`The standard governing the Board’s determination of whether to grant a
`
`motion to seal is “good cause.” Garmin Int’l, Inc. v. Cuozzo Speed Techs LLC,
`
`Case IPR2012-00001, Paper 36 at 4 (April 5, 2013) (quoting 37 C.F.R. § 42.54).
`
`The Board aims to “strike a balance between the public’s interest in maintaining a
`
`complete and understandable file history and the parties’ interest in protecting truly
`
`sensitive information.” Id.
`
`The exhibits and portions of exhibits that Patent Owners seek to file under
`
`seal fall into three categories, each of which meets the “good cause” standard to be
`
`maintained in the docket under seal and available only to the parties and Board. In
`
`each instance, the material is either the confidential information of a third party
`
`who has permitted its use in this proceeding subject to a protective order, or else
`
`consists of confidential business information that would cause competitive harm to
`
`Patent Owner Adapt were it to be disclosed publicly.
`
`2
`
`
`
`
`
`A. Confidential Third-Party Documents
`
`Exhibit 2188 (“Indivior NDA Module 3.2.P.2”) was produced by third-party
`
`Indivior, Inc. (“Indivior”) in response to a document subpoena in district court
`
`litigation between Patent Owners and a pharmaceutical manufacturer that is not a
`
`party to this IPR but seeks to make a generic naloxone product. Adapt Pharma
`
`Operations Ltd. v. Teva Pharmaceuticals, USA, Inc., No. 2:16-cv-07221-BRM-
`
`JAD; see Ex. 2194 subpoena). The document is part of the confidential New Drug
`
`Application (“NDA”) submitted by Indivior to the U.S. Food and Drug
`
`Administration (“FDA”), and it contains Indivior’s confidential business
`
`information relating to its own proposed naloxone product. Although the
`
`document was subject to a protective order in the litigation in which Indivior
`
`originally produced it, Indivior has consented to its use in this proceeding provided
`
`that it is filed under seal subject to the Board’s default protective order. See Ex.
`
`2178 (email from Indivior counsel to Adapt counsel). Accordingly, there is good
`
`cause for Exhibit 2188 to be maintained under seal.
`
`B.
`
`Financial Documents of Patent Owner Adapt
`
`Exhibit 2205 (“Vigil Decl.”) and Exhibit 2207 (“Brides Decl.”) contain the
`
`confidential financial information of Patent Owner Adapt and its corporate
`
`affiliates. These exhibits contain certain financial information drawn from the
`
`internal business records of Adapt, including the sales, by various metrics, of
`
`3
`
`
`
`
`
`Narcan® Nasal Spray on a quarterly and annual basis, and various costs associated
`
`with Adapt’s activities in connection with Narcan® Nasal Spray. The information
`
`is confidential business information that is not publicly available; it is
`
`competitively sensitive and its inclusion in the public docket would cause
`
`commercial harm to Adapt.
`
`Exhibit 2205 is a declaration of Dr. Robert Vigil, an expert witness retained
`
`by Patent Owners who addresses, inter alia, the commercial success of Narcan®
`
`Nasal Spray. Dr. Vigil relies on the confidential financial information in
`
`connection with his commercial success analysis, and Patent Owners move to seal
`
`the specific portions of Dr. Vigil’s declaration that reveal the confidential financial
`
`information. In accordance with Paragraph 5(A)(ii) of the Board’s Default
`
`Protective Order, a redacted copy of Dr. Vigil’s declaration is being filed publicly
`
`as Exhibit 2206.
`
`Exhibit 2207 is a declaration of Mr. Declan Brides, Adapt’s Vice President,
`
`Finance. Mr. Brides’s declaration and its appended Exhibit A contain the Adapt
`
`confidential financial information described above; in addition, Mr. Brides’s
`
`declaration describes the sources and methods Mr. Brides used to obtain that
`
`financial information, including information about Adapt’s business operations that
`
`is not publicly known. Because the recital and authentication of the Adapt
`
`financial information—which is then analyzed and applied to the issues in the
`
`4
`
`
`
`
`
`proceeding by Dr. Vigil—constitutes the bulk of the substantive portions of Mr.
`
`Brides’s declaration, and appended Exhibit A is a spreadsheet consisting of
`
`confidential information, Patent Owners move to seal Exhibit 2205 in its entirety.
`
`In light of the confidential nature of the information in these documents and
`
`the considerations discussed above, there is good cause to maintain this
`
`information under seal.
`
`C. Confidential Regulatory Documents Containing Confidential
`Formulation and Manufacturing Information
`
`Exhibit 2098, Exhibit 2099, Exhibit 2100, Exhibit 2101, Exhibit 2102,
`
`Exhibit 2103, Exhibit 2104, Exhibit 2105, Exhibit 2106, Exhibit 2107, Exhibit
`
`2108, and Exhibit 2109 are portions of Adapt’s NDA for Narcan® Nasal Spray.
`
`NDA materials are filed on a confidential basis with the U.S. Food and Drug
`
`Administration. The portions of the NDA submitted here contain confidential
`
`details of the formulation and manufacture of Patent Owners’ Narcan® Nasal
`
`Spray product, and the public release of these documents could benefit Patent
`
`Owners’ competitors (including competitors who may be seeking to copy Patent
`
`Owners’ product) and thereby cause competitive harm to Patent Owners.
`
`Exhibit 2201 (“Jones Decl.”) is a declaration of Dr. Stuart Jones, an expert
`
`witness retained by Patent Owners who addresses, inter alia, whether Narcan®
`
`Nasal Spray embodies the challenged claims. Dr. Jones relies on confidential
`
`formulation and manufacturing information drawn from Adapt’s NDA in
`
`5
`
`
`
`
`
`performing his analysis, and Patent Owners move to seal the specific portions of
`
`Dr. Jones’s declaration that reveal that confidential information. In accordance
`
`with Paragraph 5(A)(ii) of the Board’s Default Protective Order, a redacted copy of
`
`Dr. Jones’s declaration is being filed publicly as Exhibit 2208.
`
`Accordingly, Patent Owners move to seal these exhibits, and there is good
`
`cause for them to be maintained under seal.
`
`II.
`
`PROPOSED PROTECTIVE ORDER
`
`Pursuant to 37 CFR §§ 42.54 and 42.55(a), Patent Owners propose that the
`
`Default Protective Order found in Appendix B of the Trial Practice Guide Update
`
`(July 2019), available at https://www.uspto.gov/sites/default/files/documents/trial-
`
`practice-guide-update3.pdf be entered.
`
`III. CERTIFICATION
`
`Pursuant to 37 CFR § 42.54, Patent Owners certify that they have conferred
`
`with Petitioner regarding this motion to seal and the proposed protective order.
`
`Petitioner does not object to the entry of the default protective order. Patent
`
`Owners’ understanding is that Petitioner does not object to the motion to seal, but
`
`reserves the right to do so once it has seen Patent Owners’ submissions.
`
`
`Date: December 23, 2019
`
`
`
`Respectfully submitted,
`
`
`/Jessamyn S. Berniker/
`Jessamyn S. Berniker (Reg. No. 72,328)
`Ana C. Reyes (Admitted Pro Hac Vice)
`
`6
`
`
`
`
`
`
`
`David M. Krinsky (Reg. No. 72,339)
`Anthony H. Sheh (Reg. No. 70,576)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`T: (202) 434-5000
`F: (202) 434-5029
`jberniker@wc.com
`areyes@wc.com
`dkrinsky@wc.com
`asheh@wc.com
`
`Counsel for Patent Owner
`Adapt Pharma Operations Limited
`
`
`/Jessica Tyrus Mackay/
`Jessica Tyrus Mackay (Reg. No. 64,742)
`Ann K. Kotze (Reg. No. 76,570)
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`(313) 883-8000
`jmackay@greengriffith.com
`akotze@greengriffith.com
`
`Counsel for Patent Owner
`Opiant Pharmaceuticals, Inc.
`
`7
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned hereby certifies that a true
`
`and correct copy of the foregoing was served on December 23, 2019, by delivering
`
`a copy via electronic mail on the following attorneys of record:
`
`Yelee Y. Kim
`Janine A. Carlan
`Richard Berman
`Bradford Frese
`Christopher Yaen
`ARENT FOX LLP
`1717 K Street NW
`Washington, DC 20036
`Yelee.Kim@arentfox.com
`Janine.Carlan@arentfox.com
`Richard.Berman@arentfox.com
`Bradford.Frese@arentfox.com
`Christopher.Yaen@arentfox.com
`
`
`
`
`
`
`Jessamyn S. Berniker
`Ana C. Reyes
`David M. Krinsky
`Anthony H. Sheh
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, N.W.
`Washington, DC 20005
`jberniker@wc.com
`areyes@wc.com
`dkrinsky@wc.com
`asheh@wc.com
`EmergentNarcan@wc.com
`
`Jessica Tyrus Mackay
`Ann K. Kotze
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue
`Suite 3900
`Chicago, IL 60611
`jmackay@greengriffith.com
`akotze@greengriffith.com
`
`/Jessamyn S. Berniker/
`Jessamyn S. Berniker
`Reg. No. 72,328
`
`
`
`
`
`
`
`
`8
`
`